Trump Signs Executive Order to Reclassify Cannabis as Schedule III Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Alliance Global notes that President Donald Trump signed an executive order directing the Department of Justice to finalize the proposed rule to reclassify cannabis to a Schedule III drug and called on Congress to work to provide patients access to full-spectrum CBD products. While there was some speculation that a mandate for cannabis banking would be included in the order, the fact it was not within the EO "does not mean it can't come at another time," says the analyst, who also notes that President Trump has already announced support for cannabis banking in the past. Publicly traded companies in the cannabis space include Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN) and Trulieve Cannabis (TCNNF).
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ACB with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ACB
Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 4.320
Low
4.32
Averages
4.32
High
4.32
Current: 4.320
Low
4.32
Averages
4.32
High
4.32
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roundhill Cannabis ETF (BATS: WEED) Momentum Soars to 89.25 Amid Federal Reform Optimism
- Surging Momentum: The Roundhill Cannabis ETF's momentum score has surged to 89.25, placing it in the 89th percentile among industry peers, significantly outperforming Aurora Cannabis's score of 21.25, indicating strong investor confidence amid federal cannabis reform optimism.
- Short-Term Strength: While the ETF has shown a robust short-term performance with a 61.50% increase over the last six months, the medium-term trend remains negative, suggesting that investors should prepare for volatility and a multi-stage adjustment process.
- Policy Catalyst: President Trump's push to reschedule cannabis to Schedule 3 is viewed as the most significant federal policy shift in 50 years, which could eliminate the burdensome Section 280E tax, greatly enhancing the profitability of U.S. operators.
- 2026 Performance Decline: Despite the strong momentum, the Roundhill ETF has declined by 4.72% in 2026 so far, closing at $19.38 on Tuesday, reflecting short-term market uncertainty and volatility.
Continue Reading
Aurora Cannabis Secures EU Plant Variety Rights, Strengthening Genetic Leadership
- IP Enhancement: Aurora Cannabis has been granted plant variety rights for its proprietary cannabis strains Farm Gas™ and Sourdough™ by the EU's Community Plant Variety Office, further solidifying its leadership in global cannabis genetics and ensuring protection for its innovative achievements.
- Market Expansion Opportunity: This right provides Aurora with exclusive control over the commercial production and sale of these varieties across the 27 EU member states, which is expected to drive sales growth in the European market and enhance overall company revenue.
- Quality Assurance: Farm Gas™ and Sourdough™ are favored by patients and consumers for their high potency and desirable aromas, and Aurora's genetics platform will support the delivery of consistent, reliable premium products, further enhancing its competitive position in the market.
- R&D Investment Returns: Aurora's R&D facility is regarded as unmatched in the industry, and by securing these plant variety rights, the company can protect its investments in science and innovation, ensuring sustained growth and market leadership in the future.
Continue Reading